SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) — BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, today announced it will provide a corporate update and report its financial results for the year ended December 31, 2025 by conference call on Tuesday, March 24, 2026 at 4:30 PM EDT. Following management’s formal remarks, there will be a question-and-answer session. Participants can register for the conference by navigating to https://dpregister.com/sreg/10207584/1039b7a7360. Please note that registered participants will receive their dial-in number upon registration. For those who have not registered, to listen to the call by phone, interested parties within the U.S. should call 1-833-316-0559 and international callers should call 1-412-317-5730....

Irvine, CA, March 19, 2026 (GLOBE NEWSWIRE) — Pacific Health Care Organization, Inc., (the “Company”) (OTCQB: PFHO) filed Tuesday with the Securities and Exchange Commission (the “SEC”) its annual report on Form 10-K announcing its financial results for the fiscal year ended December 31, 2025. Results The Company reported total revenues of $6,715,175 for the year ended December 31, 2025 (“fiscal year 2025”), compared to $6,065,390 for the year ended December 31, 2024 (“fiscal year 2024”). The Company reported income from operations of $1,001,038 for fiscal year 2025, compared to income from operations of $852,623 for fiscal year 2024. The Company realized net income of $1,387,647 or $0.11 per weighted average share outstanding, basic and diluted, for fiscal year 2025, compared to net income of $883,584 or $0.07 per weighted...

David Meeker QuoteDavid Meeker QuoteDr. Shoemaker quoteDr. Shoemaker quoteIMCIVREE packagingIMCIVREE packaging with vialIMCIVREE 3D RenderIMCIVREE 3D Render— First and only FDA-approved therapy for the treatment of acquired hypothalamic obesity, a rare disease characterized by accelerated and sustained weight gain caused by hypothalamic injury or dysfunction –  — Indicated to reduce excess body weight and maintain reduction long term in adults and pediatric patients aged 4 years and older with acquired hypothalamic obesity — — Approval based on -18.4% placebo-adjusted BMI reduction achieved by setmelanotide in global Phase 3 TRANSCEND trial [N=142] — — Company to host conference call today at 7:00 p.m. ET — BOSTON, March 19, 2026 (GLOBE NEWSWIRE) — Rhythm...

Key milestones include acquisition of Iverson Design and signing PureWave Hydrogen as first tokenization client Management to host business update conference call tomorrow at 10:00 am ETBOSTON, MA, March 19, 2026 (GLOBE NEWSWIRE) — Netcapital Inc. (Nasdaq: NCPL, NCPLW, Netcapital) (the “Company”), a digital private capital markets ecosystem, today announced financial results and provided corporate highlights for the third quarter of fiscal 2026 ended January 31, 2026. In addition, management plans to host a business update conference call tomorrow, March 20, 2026, at 10:00 a.m. ET. “We completed several key transactions in fiscal Q3 2026,” said Rich Wheeless, Netcapital’s Chief Executive Officer.“We partnered with Silicon Prairie Holdings Inc., which provides critical regulatory infrastructure in support of secondary trading...

ALBUQUERQUE, N.M., March 19, 2026 (GLOBE NEWSWIRE) — ARRAY Technologies (NASDAQ: ARRY) (“ARRAY” or the “Company”), a leading global provider of solar tracking technology products, software, services and foundation solutions, announced that today, its Board of Directors (the “Board”) increased its size to provide for two additional directors and appointed Emily Cohen and Carolyne Murff to serve as independent members of the Company’s Board, effective immediately. The Board is now comprised of ten directors, of which nine are independent with the additions of Ms. Cohen and Ms. Murff. Ms. Murff was appointed as a Class I director, for a term that expires at the Company’s 2027 Annual Meeting of Stockholders, and Ms. Cohen was appointed as a Class II director, for a term that expires at the Company’s 2028 Annual Meeting of Stockholders....